Company Starts Early Access Program for Precise Single-Cell Assays
PALO ALTO, Calif., Dec. 5, 2014 /PRNewswire/ — Cellular Research today announced the commercial launch of its Precise™ targeted RNASeq assays. The company also announced the commercial availability of application-focused panels for the Precise assays, including panels designed for oncology, induced pluripotent stem cells and immunology. The company highlighted an early access program for a single cell version of the Precise product, which allows customers to start with single cells and obtain direct molecular counts of RNA transcripts.
“As an early access customer we focused on validating the technology as an upgrade over our current qPCR process. Over the last few months the assays have delivered an increase in throughput, precision and sensitivity while reducing our overall running costs,” said Dan Shoemaker, Ph.D., CSO of Fate Therapeutics, one of the early access customers for the Precise assays.
“The Precise assays use next generation sequencing in conjunction with Cellular Research’s Molecular Indexing™ technology to create a powerful, more accurate alternative to quantitative PCR (qPCR). Cellular Research has designed the Precise assays for high-throughput applications where accuracy and precision are desired, and which are currently poorly served by qPCR. With the launch of our next early access program for the Precise Single Cell Assay, we are looking to help researchers go even further and quantify transcripts from a single cell. We welcome new customers interested in participating in the program,” said Steve Fodor, Ph.D., Chief Executive Officer of Cellular Research.
The Precise assays combine molecular and sample indexing in 96 and 384 sample formats, enabling customers to sequence up to 4,608 samples in a single sequencing run without the need for additional investment in new equipment or extensive training. The assays deliver unprecedented accuracy and sensitivity for low expression targets in rare and low quantity samples. Combined with robust design and data analysis pipeline, the assays deliver a simple turnkey solution for targeted RNASeq experiments.
About Cellular Research, Inc.
Cellular Research, Inc. is a biotechnology research and development company founded by innovators from Silicon Valley and Stanford University whose mission is to develop revolutionary quantitative biology products. In addition to the Precise Assays, Cellular Research has developed and is currently offering The Pixel system, a standalone direct mRNA quantitation platform. For more information, please visit http://www.cellular-research.com/.
Martin Pieprzyk, Director Strategic Marketing
SOURCE Cellular Research, Inc.